CTRI/2024/06/068269尚未招募3 期
Comparative pharmacokinetic, pharmacodynamic, safety, efficacy and immunogenicity study of VBDNSM01 (Virchow Denosumab) versus Xgeva (Amgen Denosumab) in patients with bone metastasis from solid tumours - Nil
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female with = 18 to = 75 years.
- •2.Histological or Cytological confirmation of Breast adenocarcinoma or Prostate cancer or Non-small cell lung cancer.
- •3.Radiographic evidence of atleast 1 bone metastasis (Confirmed by X-ray, computed tomography, magnetic resonance imaging or bone scan).
- •4.Eastern Cooperative Oncology Group performance status =2.
- •5.Willing to provide written informed consent and comply with protocol requirements.
- •6.Able to communicate well with the investigator, to understand and comply with the requirements of the study.
- •7.Patients of child-bearing potential must agree to use acceptable methods of contraception (as per investigator discretion) during the study. Female patients of child bearing potential must agree to use contraceptive methods for atleast 5 months after the last dose of the drug.
排除标准
- •1.History of hypersensitivity to denosumab or prior use of denosumab.
- •2.Any of the following oral/dental conditions:
- •Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.
- •Active dental or jaw condition which requires oral surgery.
- •Planned invasive dental procedure.
- •Non-healed dental or oral surgery.
- •3.Administration of intravenous (IV) bisphosphonates, fluoride, or strontium for osteoporosis within the last 1 year or oral bisphosphonates treatment for osteoporosis in last 3 months.
- •4.Currently enrolled in or has not yet completed at least 30 days (or 5 half-lives, whichever is longer) since ending earlier investigational device or drug trial(s), or patient is receiving another investigational agent(s).
- •5.Planned bone surgery or radiation to the bone.
- •6.Life expectancy less than 6 months.
- •7.Serum calcium levels =8 mg/dl.
- •8.Estimated creatinine clearance =30 ml/min.
- •9.Females with a positive pregnancy test at screening or lactating females.
- •10.Tested positive for HIV, HCV or HBsAg or known to be tested positive.
- •11.Un controlled hypertension (Blood pressure = 140 by 90 mm of Hg). Patient on stable antihypertensive medication for more than 3 months with controlled hypertension will be eligible.
- •12.Any other significant medical condition which in the opinion of the investigator increases the safety risk if patient participate in the trial.
- •13.Clinically relevant ECG abnormality that affects the successful completion of patient’s treatment in the trial as per investigator.
- •14.Recent history (within the past 1 year) of myocardial infarction or cerebral stroke or patients with NYHA III or IV heart failure.
- •15.History of drug or alcohol abuse within the 12 months prior to dosing.
- •16.Any of the following abnormal investigational values:
- •a.General: Any laboratory abnormality which, in the opinion of the Investigator, would prevent the patient from safely completing the study or interfere with the interpretation of the study results.
- •b.Liver transaminases:
- •i.AST or SGOT =2.0 x upper limits of normal ULN;
- •ii.ALT or SGPT =2.0 x ULN;
- •iii. Alkaline phosphatase and bilirubin =1.5 x ULN.
研究者
相似试验
进行中（未招募）
3 期
Comparative biosimilar rituximab vs Ristova in Rheumatoid ArthritisCTRI/2022/10/046212Virchow Biotech Private Limited
已完成
不适用
Comparative pharmacokinetics, pharmacodynamics, efficacy and safety of two asparaginase preparations in children with previously untreated acute lymphoblastic leukaemia (ALL)CancerISRCTN75734403Medac GmbH (Germany)32
进行中（未招募）
不适用
Pharmacokinetics, efficacy, tolerability and safety evaluation of the therapy with subcutaneous immunoglobulin in the treatment of hypo or agammaglobulinaemic patients. Open label phase II/III study - NDHypogammaglobulinaemia or agammaglobulinaemiaMedDRA version: 9.1Level: LLTClassification code 10060384MedDRA version: 9.1Level: LLTClassification code 10001471EUCTR2010-020167-20-ITKEDRIO
尚未招募
不适用
This is a study to optimise the dosing regimen for Vancomycin so that patient response to the drug can be improved.CTRI/2023/02/049473Prof Nusrat Shafiq
已完成
1 期
Study to evaluate the effects of new drug of diabetes mellitus in healthy volunteers.CTRI/2016/01/006507Cadila Pharmaceuticals Ltd36